Words by GOLD newsdesk
Roche’s commitment to the World Federation of Hemophilia Humanitarian Aid Program has been extended until the end of 2028 in order to help those most in need, Bill Anderson, CEO Roche Pharmaceuticals has announced.
The renewed commitment aims to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to diagnosis, treatment and care.
Originally formed in 2019, the partnership marked the first time that patients in developing countries received access to a prophylactic treatment for haemophilia, and it has since benefitted in excess of 940 people across 30 countries.
In developing countries, limited healthcare resources are often reserved for emergency situations and acute bleeds. Where prophylactic treatments are available, they tend to be administered in low-doses, which don’t offer the standard of care that is considered to be the ‘gold standard’ for the condition.
“Last year was a record year for the WFH Humanitarian Aid Program, which continues to make life-changing treatment accessible for those who need it most,” said Cesar Garrido, WFH President. “With Roche’s continued support, we will be able to continue the important work that the Humanitarian Aid Program does, giving people with bleeding disorders the hope of leading a normal life through prophylactic treatment.”
In total, more than 22,000 people with haemophilia in over 112 countries have been treated with prophylactic and on-demand treatment thanks to the WFH Humanitarian Aid Program.